Latest news
{{'2025-11-10T13:45:00Z' | dateFormatFilter}}
Novo Nordisk’s Wegovy® (semaglutide 2.4 mg) was associated with liver health-related benefits not solely based on weight loss in adult patients with MASH with liver scarring, according to a new post hoc analysis
{{'2025-11-08T08:19:11Z' | dateFormatFilter}}
Novo Nordisk will not increase its proposal to acquire Metsera, Inc.
{{'2025-11-06T19:30:00Z' | dateFormatFilter}}
Novo Nordisk's CagriSema associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®
Progress towards zero environmental impact
Being respected for adding value to society
Ensure distinct core capabilities and evolve culture
Further raise the innovation-bar for diabetes treatment
Develop a leading portfolio of superior treatment solutions for obesity
Strengthen and progress the Rare disease pipeline
Establish presence in Other serious chronic diseases focusing on CVD, NASH and CKD
Strengthen Diabetes leadership - aim at global value market share of more than 1/3
More than 25 billion DKK in Obesity sales by 2025
Secure a sustained growth outlook for Rare disease
Deliver solid sales and operating profit growth:
- Deliver 6-10% sales growth in International Operations
- Transform 70% of sales in the USA1
Drive operational efficiencies across the value chain to enable investments in future growth assets
Deliver free cash flow to enable attractive capital allocation to shareholders
Investors
Share price
{{priceData.date}} {{priceData.time}}